Medifocus Inc. is Pleased to Announce the Appointment of Ernie Eves, QC, to the Board of Directors

COLUMBIA, Md.--(BUSINESS WIRE)-- Medifocus Inc. (OTC:MDFZF.PK) (TSXV:MFS) a medical device company currently in Phase III clinical studies for the treatment of Breast Cancer, is pleased to announce the appointment of Ernie Eves, QC, to the Board  of Directors of Medifocus Inc.

Mr. Eves is the Former Premier of the Province of Ontario. As Premier, his responsibilities encompassed a budget of more than $70 billion and 65,000 employees. Prior to serving as Premier, he was Deputy Premier and Minister of Finance. He held numerous portfolios during his 24 years in public life which began as a member of the Provincial Legislature in 1981.

Mr. Eves has had a distinguished career in both the public and private sectors. Currently, he is the Executive Chairman of Jacob Securities Inc., an investment bank. He currently serves as an advisor and board member for several firms in Canada and the United States.

Ernie Eves is a graduate of Osgoode Hall Law School. He was called to the bar in 1972 and in 1983 was made a Queen’s Counsel.

About  Medifocus Inc.

Medifocus is a medical device company which owns a patented microwave focusing technology platform, the Adaptive Phased Array ("APA") system, which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness over those treatments alone. The core technology has been exclusively licensed from the Massachusetts Institute of Technology (MIT).  Medifocus has completed the development of a dedicated  cancer treatment system for the treatment of breast cancer.  Medifocus has received approval from both the USA FDA and Health Canada to begin its Pivotal Phase III Clinical Study.



CONTACT:

Medifocus Inc.
John Mon, COO
410-290-5734
[email protected]

KEYWORDS:   United States  North America  Canada  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Other Health

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.